Recent applications of genome sequencing on NKTCL patients revealed recurrent mutational targets such as RNA helicase (e.g., DDX3X), tumor suppressors (e.g., TP53), and genes involved in the JAK-STAT and RAS-MAPK signaling pathways, as well as epigenetic modulators (e.g., KMT2C and KMT2D) [7–9]. This evidence concerns the gene TP53 and extranodal nasal NK/T cell lymphoma.